BSECHOKSI LABORATORIES LTD.MediumNegative
Announced Wed, 21 Oct, 2026 · 18:41 IST

Company clarifies delay in EGM proceedings submission; preferential warrants issue

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-4.4%Reaction day
₹219.70
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.0%-3.4% vs market
Healthcare Service Provider peers, median of 26sector+0.2%-4.7% vs sector

On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 4.7 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-4.4-1.0-3.4+0.2-4.7
Next day
-4.4-3.3-1.1-0.9-3.5
2d
-2.6-2.9+0.3+0.5-3.1
3d
-2.1pendingpending+2.1-4.3
4d
—————
5d
—————
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Choksi Laboratories clarified to BSE the inadvertent delay in submitting proceedings of its EGM held on October 17, 2026 via video conferencing. The six-minute EGM (12.33 to 12.39 PM) considered a special resolution to issue convertible warrants on a preferential basis. Promoters and proposed allottees abstained from voting. Remote e-voting ran October 14 to 16 with October 10 cut-off. Scrutinizer Ms. Surbhi Agrawal will submit her report within 48 hours. The company termed the delay technical.

Likely market impact

Minor compliance delay with no business impact. Key item is the proposed preferential issue of convertible warrants awaiting shareholder approval.